Abstract
5054 Background: The purpose of this study is to evaluate the feasibility of IV / IP paclitaxel and IP carboplatin (TCipTip therapy) in patients with epithelial ovarian, fallopian tube or peritoneal carcinoma. Methods: From December 2007 to August 2010, the women with histologically confirmed, stage Ic-IVepithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma were received 6 cycle of TCipTip therapy after primary cytoreductive surgery. IV paclitacxel was administered at 135 mg/m2 followed by IP carboplatin administration based on the AUC = 6 on day1, and IP paclitacxel was administered at 60 mg/m2 on day 8. The toxicity grade was determined by CTCAE version 3.0. Progression free survival and Overall survival were estimated using Kaplan-Meier method. This study had been approved by the institutional review committee. The institutional review board required us to administer 45mg/m2 of IP paclitaxel at first cycle for the first 3 women to make sure the safety. Results: Twenty women entered in this study. They included 18 epithelial ovarian carcinomas (stage Ic, 8; stage IIc, 2; stage IIIc, 7; stage IV, 1), 1 stage IIc fallopian tube carcinoma and 1 stage IV primary peritoneal carcinoma. There were 12 serous, 5 endometrioid, 1 mucinous, 1 clear cell adenocarcinoma, and 1 mixed carcinoma. Eleven women achieved optimal status at primary surgery. Incidences of grade 3/4 hematological toxicities were 73% for neutrocytopenia, 9% for thrombocytopenia, and 24% for anemia. Observed grade 3/4 non-hematological toxicities were 4 for grade 3 allergy, 1 for grade 3 ileus. Ten patients completed more than 6 cycles of chemotherapy. The reasons of interruption were 3 for allergy to paclitaxel, 2 for abdominal pain, 1 for allergy to carboplatin, 1 for disease progression, 1 for pleural embolism, 1 for ileus, 1 for change of address. The PFS and OS at 2years were 85% and 47%, respectively. Conclusions: The toxicities by TCipTip therapy were acceptable, and this therapy is feasible for patients with epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma. Further evaluation about TCipTip therapy is warranted.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
